Digestive Diseases and Sciences

, Volume 52, Issue 4, pp 897–907 | Cite as

Cryoglobulinemia Related to Hepatitis C Virus Infection

  • Maria Pina Dore
  • Giovanna Fattovich
  • Antonia R. Sepulveda
  • Giuseppe Realdi
Review article

Abstract

A causal link among hepatitis C virus (HCV) infection and essential mixed cryoglobulinemia, cryoglobulinemic glomerulonephritis, and vasculitis is strongly supported. HCV triggers autoimmune response in predisposed individuals that manifests as organ-specific and non–organ-specific autoantibodies and as polyclonal/monoclonal rheumatoid factor, which has a central role in causing damaging cryoglobulin and immune complex tissue levels. Immunologic events are mainly induced by HCV infection persistence, with excessive immune stimulation. Humoral immune dysfunction leads to autoantibodies and rheumatoid factor production with cryoglobulinemia, glomerulonephritis, vasculitis, neuropathy, and probably thyroiditis, and arthritis in rare cases. Cellular immune dysfunction leads to lymphocytic infiltration, proliferation, and cytokine production. Pegylated (or not) interferon-alpha in combination with ribavirin appears to be the treatment of choice for patients with symptomatic essential mixed cryoglobulinemia with or without glomerulonephritis. Novel treatment with rituximab is promising.

Keywords

Mixed cryoglobulinemia Extrahepatic manifestations Autoimmune disorders 

References

  1. 1.
    Lorber B (1996) Are all diseases infectious? Ann Intern Med 125:844–851PubMedGoogle Scholar
  2. 2.
    Ramos-Casals M, Jara LJ, Medina F, Rosas J, Calvo-Alen J, Mana J, Anaya JM, Font J, HISPAMEC Study Group (2005) Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 257:549–557PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002) Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36:1439–1445PubMedGoogle Scholar
  4. 4.
    Gumber SC, Chopra S (1995) Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 123:615–620PubMedGoogle Scholar
  5. 5.
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463–472PubMedCrossRefGoogle Scholar
  6. 6.
    Major ME, Feinstone SM (1997) The molecular virology of hepatitis C. Hepatology 25:1527–1538PubMedCrossRefGoogle Scholar
  7. 7.
    Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Remire J, Soussy CJ, Dhumeaux D (1998) What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 27:1700–1702PubMedCrossRefGoogle Scholar
  8. 8.
    Martinot-Peignoux M, Boyer N, Le Breton V, Le Guludec G, Castelnau C, Akremi R, Marcellin P (2000) A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology 31:726–729PubMedCrossRefGoogle Scholar
  9. 9.
    Zignego AL, De Carli M, Monti M, Careccia G, La Villa G, Giannini C, D'Elios MM, Del Prete G, Gentilini P (1995) Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 47:58–64PubMedCrossRefGoogle Scholar
  10. 10.
    Shimizu YK, Weiner AJ, Rosenblatt J, Wong DC, Shapiro M, Popkin T, Houghton M, Alter HJ, Purcell RH (1990) Production of antibody associated with non-A, non-B hepatitis in a chimpanzee lymphoblastoid cell line established by in vitro transfection with Epstein-Barr virus. Proc Natl Acad Sci USA 87:6441–6444PubMedCrossRefGoogle Scholar
  11. 11.
    Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH (1992) Lack of protection against reinfection with hepatitis C virus. Science 258:135–140PubMedCrossRefGoogle Scholar
  12. 12.
    Sansonno D, Cornacchiulo V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F (1995) Localization of hepatitis C virus antigens in liver and skin tissue of chronic hepatitis C virus–infected patients with mixed cryoglobulinemia. Hepatology 21:305–312PubMedGoogle Scholar
  13. 13.
    Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F (1997) Hepatitis C virus–related proteins in kidney tissue from hepatitis C virus–infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25:1237–1244PubMedCrossRefGoogle Scholar
  14. 14.
    Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5:227–236PubMedCrossRefGoogle Scholar
  15. 15.
    Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, Dammacco F (2003) Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 133:275–282PubMedCrossRefGoogle Scholar
  16. 16.
    Daghestani L, Pomeroy C (1999) Renal manifestations of hepatitis C infection. Am J Med 106:347-354PubMedCrossRefGoogle Scholar
  17. 17.
    Sim RB, Moestrup SK, Stuart GR, Lynch NJ, Lu J, Schwaeble WJ, Malhotra R (1998) Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Immunobiology 199:208–224PubMedGoogle Scholar
  18. 18.
    Ghebrehiwet B, Peerschke EI (1998) Structure and function of gC1q-R: a multiligand binding cellular protein. Immunobiology 199:225–238PubMedGoogle Scholar
  19. 19.
    Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B (2002) Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol 168:2441–2448PubMedGoogle Scholar
  20. 20.
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938–941PubMedCrossRefGoogle Scholar
  21. 21.
    Ichiki Y, He XS, Shimoda S, Ishibashi H, Keeffe EB, Rossaro L, Gershwin ME (2005) T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev 4:82–95PubMedCrossRefGoogle Scholar
  22. 22.
    Freni MA, Artuso D, Gerken G, Spanti C, Marafioti T, Alessi N, Spadaro A, Ajello A, Ferrau O (1995) Focal lymphocytic aggregates in chronic hepatitis C: occurrence, immunohistochemical characterization, and relations to markers of autoimmunity. Hepatology 22:389–394PubMedGoogle Scholar
  23. 23.
    Mosnier JF, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou JP (1993) The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology 17:366–371PubMedCrossRefGoogle Scholar
  24. 24.
    Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F (2001) Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus–infected patients. J Immunol 167:21–29PubMedGoogle Scholar
  25. 25.
    Bertoletti A, DíElios MM, Boni C, De Carli M, Zignego AL, Durazzo M, Missale G, Penna A, Fiaccadori F, Del Prete G, Ferrari C (1997) Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 112:193–199PubMedCrossRefGoogle Scholar
  26. 26.
    Manns MP, Rambusch EG (1999) Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 31(Suppl 1):39–42PubMedCrossRefGoogle Scholar
  27. 27.
    Lenzi M, Johson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, Bridger C, Vergani D, Bianchi FB, Williams R (1991) Antibodies to hepatitis C virus in auto-immune liver disease: evidence for geographical heterogeneity. Lancet 338:277–280PubMedCrossRefGoogle Scholar
  28. 28.
    Bianchi FB (1993) Auto-immune hepatitis: the lesson of the discovery of hepatitis C virus. J Hepatol 18:273–275PubMedCrossRefGoogle Scholar
  29. 29.
    Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB (1997) Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25:1105–1107PubMedCrossRefGoogle Scholar
  30. 30.
    Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, Callard P, Beaugrand M (1992) Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339:321–323PubMedCrossRefGoogle Scholar
  31. 31.
    Divano MC, Parodi A, Rebora A (1992) Lichen planus, liver kidney microsomal (LKM-1) antibodies and hepatitis C virus antibodies. Dermatology 185:132–133PubMedCrossRefGoogle Scholar
  32. 32.
    Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF (1999) Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 50:503–509CrossRefGoogle Scholar
  33. 33.
    Custro N, Montalto G, Scafidi V, Soresi M, Gallo S, Tripi S, Notarbartolo A (1997) Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 25:938–946Google Scholar
  34. 34.
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R (1993) Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465–470PubMedCrossRefGoogle Scholar
  35. 35.
    Cacoub P, Lunel-Fabiani F, Du LT (1992) Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 7:605–606Google Scholar
  36. 36.
    Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333PubMedCrossRefGoogle Scholar
  37. 37.
    Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O'Rahilly S, Shore S, Tom BD, Alexander GJ (1999) Further evidence for an association between non–insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059–1063PubMedCrossRefGoogle Scholar
  38. 38.
    Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599PubMedGoogle Scholar
  39. 39.
    Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, Bierling P (1995) Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol 23:635–639PubMedCrossRefGoogle Scholar
  40. 40.
    Eddy S, Wim R, Peter VE, Tanja R, Jan T, Werner VS (1999) Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 44:186–189PubMedCrossRefGoogle Scholar
  41. 41.
    Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G (2003) HCV infection and extrahepatic manifestations. Hepatogastroenterology 50:1149–1154PubMedGoogle Scholar
  42. 42.
    Lunel F (1994) Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 107:1550–1554PubMedGoogle Scholar
  43. 43.
    Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, Bianchi FB (1995) Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 37:406–412PubMedGoogle Scholar
  44. 44.
    Michel G, Ritter A, Gerken G, Meyer zum Buschenfelde KH, Decker R, Manns MP (1992) Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339:267–269PubMedCrossRefGoogle Scholar
  45. 45.
    Koskinas J, McFarlane BM, Nouri-Aria KT, Tibbs CJ, Mizokami M, Donaldson PT, McFarlane IG, Williams R (1994) Cellular and humoral immune reactions against autoantigens and hepatitis C viral antigens in chronic hepatitis C. Gastroenterology 107:1436–1442PubMedGoogle Scholar
  46. 46.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1995) Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 40:2098–2106PubMedCrossRefGoogle Scholar
  47. 47.
    Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18:54–63PubMedCrossRefGoogle Scholar
  48. 48.
    Brouet JC, Clouvel JP, Darun F, Klein M, Seligmann M (1974) Biological and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 57:775–788PubMedCrossRefGoogle Scholar
  49. 49.
    Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, Franklin EC (1980) Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69:287–308PubMedCrossRefGoogle Scholar
  50. 50.
    D'Amico G, Colasanti G, Ferrario F, Sinico RA (1989) Renal involvement in essential mixed cryoglobulinemia. Kidney Int 35:1004–1014PubMedGoogle Scholar
  51. 51.
    Realdi G, Alberti A, Rigoli A, Tremolada F (1974) Immune complexes and Australia antigen in cryoglobulinemic sera. Z Immun Forsch 147:114–126Google Scholar
  52. 52.
    Levo Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC (1977) Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 296:1501–1504PubMedCrossRefGoogle Scholar
  53. 53.
    Pascual M, Perrin L, Giostra E, Schifferli JA (1990) Hepatitis C virus in patients with cryoglobulinemia type II [Letter]. J Infect Dis 162:569–570PubMedGoogle Scholar
  54. 54.
    Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, Sulfaro S, Franzin F, Tulissi P, Moretti M (1994) Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 84:3047–3053PubMedGoogle Scholar
  55. 55.
    Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, Comotti B, Tanzi E, Scudeller G, Zanetti A (1992) Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573–577PubMedGoogle Scholar
  56. 56.
    Monteverde A (1996) Le crioglobulinemie miste. In Atti del 97° Congresso della Società Italiana di Medicina Interna. L. Pozzi (ed), pp 3–152Google Scholar
  57. 57.
    Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Valla D, Piette JC (1994) Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106:1291–1300PubMedGoogle Scholar
  58. 58.
    Agnello V (1997) The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19:111–129PubMedCrossRefGoogle Scholar
  59. 59.
    Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection and type II cryoglobulinemia. N Engl J Med 327:1490–1495PubMedCrossRefGoogle Scholar
  60. 60.
    Perl A, Wang N, Williams JM, Hunt MJ, Rosenfeld SI, Condemi JJ, Packman CH, Abraham GN (1987) Aberrant immunoglobulin and c-myc gene rearrangements in patients with nonmalignant monoclonal cryoglobulinemia. J Immunol 139:3512–3520PubMedGoogle Scholar
  61. 61.
    Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L (2002) Cryoglobulinemia vasculitis. Curr Opin Rheumatol 14:29–35PubMedCrossRefGoogle Scholar
  62. 62.
    Dammacco F, Sansonno D (1997) Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 15:97–119PubMedGoogle Scholar
  63. 63.
    Abel G, Zhang QX, Agnello V (1993) Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 36:1341–1349PubMedCrossRefGoogle Scholar
  64. 64.
    Willson RA (1997) Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 92:4–17Google Scholar
  65. 65.
    De Vita S, De Re V, Sansonno D, Sorrentino D, Corte RL, Pivetta B, Gasparotto D, Racanelli V, Marzotto A, Labombarda A, Gloghini A, Ferraccioli G, Monteverde A, Carbone A, Dammacco F, Boiocchi M (2000) Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 31:182–189PubMedCrossRefGoogle Scholar
  66. 66.
    Mazzaro C, Zagonel V, Monfardini S, Tulissi P, Pussini E, Fanni M, Sorio R, Bortolus R, Crovatto M, Santini G, Tiribelli C, Sasso F, Masutti R, Pozzato G (1996) Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol 94:544–550PubMedCrossRefGoogle Scholar
  67. 67.
    Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966) Cryoglobulinemia—a clinical and laboratory study II. Cryoglobulins with rheumatoid factor activity. Am J Med 40:837–856PubMedCrossRefGoogle Scholar
  68. 68.
    Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, Morselli M, Emilia G, Torelli G (1996) Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 94:373–375PubMedCrossRefGoogle Scholar
  69. 69.
    Rasul I, Shepherd FA, Kamel-Reid S, Krajden M, Pantalony D, Heathcote EJ (1999) Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 29:543–547PubMedCrossRefGoogle Scholar
  70. 70.
    Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G, Gentilini P (2000) T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 31:474–479PubMedCrossRefGoogle Scholar
  71. 71.
    Kitay-Cohen Y, Amiel A, Hilzenrat N, Buskila D, Ashur Y, Fejgin M, Gaber E, Safadi R, Tur-Kaspa R, Lishner M (2000) Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 96:2910–2912PubMedGoogle Scholar
  72. 72.
    Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM (2001) The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97:1555–1559PubMedCrossRefGoogle Scholar
  73. 73.
    Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L, Ponticelli C (1995) Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 47:618–623PubMedGoogle Scholar
  74. 74.
    Tarantino A, Moroni G, Banfi G, Manzoni C, Segagni S, Ponticelli C (1994) Renal replacement therapy in cryoglobulinaemic nephritis. Nephrol Dial Transplant 9:1426–1430PubMedGoogle Scholar
  75. 75.
    Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27:2172–2178PubMedGoogle Scholar
  76. 76.
    Bonomo L, Casato M, Afeltra A, Caccavo D (1987) Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83:726–730PubMedCrossRefGoogle Scholar
  77. 77.
    Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A (1994) Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751–756PubMedCrossRefGoogle Scholar
  78. 78.
    Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Valla D, Piette JC (1994) Cryoglobulinemia in chronic liver diseases: role of HCV and liver damage. Gastroenterology 106:1291–300PubMedGoogle Scholar
  79. 79.
    Ferri C, Marzo E, Longomabardo G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A (1993) Interferon-alpha in mixed cryoglobulinemia patients: A randomized crossover-controlled trial. Blood 81:1132–1136PubMedGoogle Scholar
  80. 80.
    Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84:3336–3343PubMedGoogle Scholar
  81. 81.
    Ferri C, Marzo E, Longomabardo G, Lombardini F, La Civita L, Vanacore R, Gentilini P, Bombardieri S, Zignego AL (1993) Interferon-alpha in mixed cryoglobulinemia patients: a randomized crossover-controlled trial. Blood 81:1132–1136PubMedGoogle Scholar
  82. 82.
    Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L (1991) Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78:3142–3147PubMedGoogle Scholar
  83. 83.
    Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, Mazzilli C, Antonelli G, Bonomo L (1997) Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90:3865–3873PubMedGoogle Scholar
  84. 84.
    Cid MC, Hernandez-Rodriguez J, Robert J, del Rio A, Casademont J, Coll-Vinent B, Grau JM, Kleinman HK, Urbano-Marquez A, Cardellach F (1999) Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 42:1051–1055PubMedCrossRefGoogle Scholar
  85. 85.
    Suzuki H, Takei T, Tsuji H, Nishikawa T (2000) Membranoproliferative glomerulonephritis and demyelinating neuropathy caused by type II mixed cryoglobulinemia associated with HCV infection. Intern Med 39:397–400PubMedGoogle Scholar
  86. 86.
    Zuckerman, E, Keren, D, Slobodin, G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27:2172–2178PubMedGoogle Scholar
  87. 87.
    Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P (2004) Influence of antiviral therapy in hepatitis C virus–associated cryoglobulinemic MPGN. Am J Kidney Dis 43:617–623PubMedCrossRefGoogle Scholar
  88. 88.
    Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G (2005) Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus–associated mixed cryoglobulinemia: a pilot study. J Hepatol 42:632–638PubMedCrossRefGoogle Scholar
  89. 89.
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O (2005) PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52:911–915PubMedCrossRefGoogle Scholar
  90. 90.
    Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM (2005) Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32:1164-1167PubMedGoogle Scholar
  91. 91.
    Kamar N, Rostaing L, Alric L (2006) Treatment of hepatitis C virus–related glomerulonephritis. Kidney Int 69:436–439PubMedCrossRefGoogle Scholar
  92. 92.
    Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818–3826PubMedCrossRefGoogle Scholar
  93. 93.
    Zaja F, De Vita S, Mazzaro C (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834PubMedCrossRefGoogle Scholar
  94. 94.
    Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitar J, Lavayssiere L, Oksman F, Dur D, Rostaing L (2005) Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 15:1560–1564CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Maria Pina Dore
    • 1
  • Giovanna Fattovich
    • 2
  • Antonia R. Sepulveda
    • 4
  • Giuseppe Realdi
    • 3
  1. 1.Istituto di Clinica MedicaUniversity of SassariSassariItaly
  2. 2.Dipartimento di GastroenterologiaUniversity of VeronaVeronaItaly
  3. 3.Clinica Medica IUniversity of PadovaPadovaItaly
  4. 4.Department of PathologyUniversity of Pittsburgh, Medical CenterPittsburghUSA

Personalised recommendations